• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶受体在体内细胞迁移中的非蛋白水解作用。

Nonproteolytic role for the urokinase receptor in cellular migration in vivo.

作者信息

Waltz D A, Fujita R M, Yang X, Natkin L, Zhuo S, Gerard C J, Rosenberg S, Chapman H A

机构信息

Department of Medicine, Children's Hospital, Boston, Massachusetts 02115, USA.

出版信息

Am J Respir Cell Mol Biol. 2000 Mar;22(3):316-22. doi: 10.1165/ajrcmb.22.3.3713.

DOI:10.1165/ajrcmb.22.3.3713
PMID:10696068
Abstract

The urokinase receptor (uPAR) binds and localizes urokinase activity at cellular surfaces, facilitating fibrinolysis and cellular migration at sites of tissue injury. uPAR also participates in cellular signaling and regulates integrin-dependent adhesion and migration in vitro. We now report evidence that uPAR occupancy regulates cellular migration in vivo in the absence of functional urokinase. Recombinant murine KC (1.5 microg), a potent neutrophil chemoattractant, was delivered to the lungs of wild-type, urokinase-deficient or uPAR-deficient mice 18 h after intraperitoneal injection of 200 microg human immunoglobulin G (IgG) or a fusion protein composed of an amino-terminal receptor-binding fragment of urokinase and a human IgG Fc fragment (GFD-Fc). Whole lung lavage for recovery of leukocytes was performed 4 h later. KC treatment resulted in a 100-fold increase in lavage neutrophils. GFD-Fc injection resulted in >50% reduction in neutrophil influx in both wild-type and urokinase-deficient animals but had no effect on uPAR -/- mice. A concomitant reduction in alveolar protein leakage but no change in numbers of circulating neutrophils accompanied this attenuated inflammatory response. The reduction in neutrophil influx induced by GFD-Fc is thus related to uPAR occupancy and yet not due to disruption of uPAR-mediated proteolysis. These observations verify that protease-independent functions of uPAR operate in vivo and identify uPAR as a potential target for regulation of inflammatory processes characterized by neutrophil-mediated injury.

摘要

尿激酶受体(uPAR)可结合尿激酶并将其活性定位在细胞表面,促进组织损伤部位的纤维蛋白溶解和细胞迁移。uPAR还参与细胞信号传导,并在体外调节整合素依赖性黏附和迁移。我们现在报告证据表明,在缺乏功能性尿激酶的情况下,uPAR的占据可调节体内细胞迁移。在腹腔注射200μg人免疫球蛋白G(IgG)或由尿激酶的氨基末端受体结合片段和人IgG Fc片段组成的融合蛋白(GFD-Fc)18小时后,将重组鼠KC(1.5μg),一种有效的中性粒细胞趋化因子,注入野生型、尿激酶缺陷型或uPAR缺陷型小鼠的肺部。4小时后进行全肺灌洗以回收白细胞。KC治疗导致灌洗中性粒细胞增加100倍。GFD-Fc注射导致野生型和尿激酶缺陷型动物的中性粒细胞流入减少>50%,但对uPAR -/-小鼠没有影响。这种减弱的炎症反应伴随着肺泡蛋白渗漏的同时减少,但循环中性粒细胞数量没有变化。因此,GFD-Fc诱导的中性粒细胞流入减少与uPAR的占据有关,但不是由于uPAR介导的蛋白水解的破坏。这些观察结果证实了uPAR的蛋白酶非依赖性功能在体内起作用,并确定uPAR是调节以中性粒细胞介导的损伤为特征的炎症过程的潜在靶点。

相似文献

1
Nonproteolytic role for the urokinase receptor in cellular migration in vivo.尿激酶受体在体内细胞迁移中的非蛋白水解作用。
Am J Respir Cell Mol Biol. 2000 Mar;22(3):316-22. doi: 10.1165/ajrcmb.22.3.3713.
2
Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.尿激酶型纤溶酶原激活物受体促进巨噬细胞浸润到载脂蛋白E缺陷小鼠的血管壁中。
J Cell Physiol. 2005 Jul;204(1):73-82. doi: 10.1002/jcp.20262.
3
Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.尿激酶型纤溶酶原激活物受体(uPAR)在中性粒细胞跨内皮迁移中的作用。
Mol Immunol. 2011 May;48(9-10):1168-77. doi: 10.1016/j.molimm.2011.02.011. Epub 2011 Apr 5.
4
Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.尿激酶型纤溶酶原激活剂与其受体结合,通过增强整合素介导的信号转导来刺激肿瘤细胞迁移。
Exp Cell Res. 1999 Jul 10;250(1):231-40. doi: 10.1006/excr.1999.4510.
5
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection.尿激酶受体缺陷型小鼠在应对肺部铜绿假单胞菌感染时,中性粒细胞募集功能受损。
J Immunol. 2000 Aug 1;165(3):1513-9. doi: 10.4049/jimmunol.165.3.1513.
6
Urokinase-type plasminogen activator receptor plays a role in neutrophil migration during lipopolysaccharide-induced peritoneal inflammation but not during Escherichia coli-induced peritonitis.尿激酶型纤溶酶原激活物受体在脂多糖诱导的腹膜炎症中对中性粒细胞迁移起作用,但在大肠杆菌诱导的腹膜炎中不起作用。
J Infect Dis. 2006 Feb 15;193(4):522-30. doi: 10.1086/499601. Epub 2006 Jan 5.
7
Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro.尿激酶缺陷型和尿激酶受体缺陷型小鼠在体外的中性粒细胞抗菌激活功能受损。
J Leukoc Biol. 2004 Sep;76(3):648-56. doi: 10.1189/jlb.0104023. Epub 2004 Jul 7.
8
Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2' CD11b/CD18) during neutrophil polarization.在中性粒细胞极化过程中,尿激酶型纤溶酶原激活物受体与补体3型受体(αMβ2,CD11b/CD18)可逆性解离。
J Immunol. 1996 Jan 1;156(1):297-309.
9
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.白细胞介素-1α通过调节α6β1整合素和尿激酶型纤溶酶原激活剂受体的表达增强胰腺癌细胞的侵袭行为。
BMC Cell Biol. 2006 Feb 20;7:8. doi: 10.1186/1471-2121-7-8.
10
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.尿激酶型纤溶酶原激活物受体(uPAR)在血液和骨髓细胞上的结构、功能及表达
Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398.

引用本文的文献

1
Assessment of Serum suPAR Levels in Patients with Group 1 and Group 4 Pulmonary Hypertension.1组和4组肺动脉高压患者血清可溶性尿激酶型纤溶酶原激活物受体水平的评估
J Clin Med. 2025 Jul 2;14(13):4671. doi: 10.3390/jcm14134671.
2
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.采用多标志物筛查鉴定与房颤患者心血管死亡相关的生物标志物。
Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
3
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
心血管-肾脏生物标志物可溶性尿激酶型纤溶酶原激活物受体与冠心病患者心血管死亡和心肌梗死相关,与肌钙蛋白、C 反应蛋白和肾功能无关。
J Am Heart Assoc. 2020 Apr 21;9(8):e015452. doi: 10.1161/JAHA.119.015452. Epub 2020 Apr 17.
4
Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow.冠状动脉血流缓慢患者循环中可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平升高。
Arch Med Sci Atheroscler Dis. 2016 Jun 22;1(1):e53-e59. doi: 10.5114/amsad.2016.60819. eCollection 2016.
5
spp.: A Promising Adjuvant Treatment for Breast Cancer.spp.:一种有前景的乳腺癌辅助治疗方法。
Medicines (Basel). 2017 Mar;4(1). doi: 10.3390/medicines4010015. Epub 2017 Mar 15.
6
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.可溶性尿激酶型纤溶酶原激活物受体可预测缺血性脑卒中及短暂性脑缺血发作患者的5年全因死亡率。
In Vivo. 2017 May-Jun;31(3):381-386. doi: 10.21873/invivo.11070.
7
Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.特定通路聚集生物标志物风险评分与冠状动脉疾病负担相关,并可预测心肌梗死和死亡的近期风险。
Circ Cardiovasc Qual Outcomes. 2017 Mar;10(3). doi: 10.1161/CIRCOUTCOMES.115.001493.
8
Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy.炎症和N-甲酰肽受体介导增殖性糖尿病视网膜病变中人类玻璃体液的血管生成活性。
Diabetologia. 2017 Apr;60(4):719-728. doi: 10.1007/s00125-016-4204-0. Epub 2017 Jan 13.
9
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.尿激酶型纤溶酶原激活剂及其受体在临床和小鼠模型中局灶节段性肾小球硬化进展中的意义。
J Biomed Sci. 2016 Feb 4;23:24. doi: 10.1186/s12929-016-0242-7.
10
Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.可溶性尿激酶型纤溶酶原激活物受体水平是冠状动脉疾病的存在、严重程度及未来不良事件的独立预测指标。
J Am Heart Assoc. 2014 Oct 23;3(5):e001118. doi: 10.1161/JAHA.114.001118.